期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 45, 期 7, 页码 983-990出版社
WILEY
DOI: 10.1111/apt.13961
关键词
-
资金
- University of Nottingham/Nottingham Hospitals Nottingham NHS Senior Clinical Research Fellowship
- Medical Research Council [MR/N005953/1] Funding Source: researchfish
- MRC [MR/N005953/1] Funding Source: UKRI
BackgroundAmong patients with cirrhosis, only those determined to be at risk for hepatocellular carcinoma (HCC) should undergo surveillance. However, little is known about how different aetiologies of cirrhosis affect risk for HCC. AimTo quantify the cumulative incidence of HCC among a representative population of people with cirrhosis of the liver of varying aetiology. MethodsWe identified subjects with hepatic cirrhosis from the UK's General Practice Research Database (1987-2006). Diagnoses of HCC were obtained from linked national cancer registries (1971-2006). Cox proportional hazards regression was used to estimate hazard ratios. The predicted 10-year cumulative incidence of HCC for each aetiology of cirrhosis was estimated while accounting for competing risks of death from any cause and liver transplant. ResultsAmong 3107 people with cirrhosis, the adjusted relative risk of HCC was increased twofold to threefold among people with viral and autoimmune/metabolic aetiologies, compared to those with alcohol-associated cirrhosis. The 10-year predicted cumulative incidence estimates of HCC for each aetiology were alcohol, 1.2%; chronic viral hepatitis, 4.0%; autoimmune or metabolic disease, 3.2%; and cryptogenic, 1.1%. ConclusionsIn a population-based study in the UK, people with cirrhosis have an estimated cumulative 10-year incidence of HCC of 4% or lower. Cumulative incidence varies with aetiology such that individuals with alcohol or cryptogenic cirrhosis have the lowest risk for HCC. These findings provide important information for cost-effectiveness analyses of HCC surveillance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据